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Background: Substantial recent advances in the comprehension of the molecular and cellular mechanisms
behind asthma have evidenced the importance of the lung immune environment for disease outcome, mak-
ing modulation of local immune responses an attractive therapeutic target against this pathology. Live atten-
uated mycobacteria, such as the tuberculosis vaccine BCG, have been classically linked with a type 1
response, and proposed as possible modulators of the type 2 response usually associated with asthma.
Methods: In this study we used different acute and chronic murine models of asthma to investigate the thera-
peutic efficacy of intranasal delivery of the live tuberculosis vaccines BCG and MTBVAC by regulating the lung
immune environment associated with airway hyperresponsiveness (AHR).
Findings: Intranasal administration of BCG, or the novel tuberculosis vaccine candidate MTBVAC, abrogated
AHR-associated hallmarks, including eosinophilia and lung remodeling. This correlated with the re-polariza-
tion of allergen-induced M2 macrophages towards an M1 phenotype, as well as with the induction of a
strong allergen-specific Th1 response. Importantly, vaccine treatment was effective in a scenario of estab-
lished chronic asthma where a strong eosinophil infiltration was already present prior to immunization. We
finally compared the nebulization efficiency of clinical formulations of MTBVAC and BCG using a standard
commercial nebulizer for potential aerosol application.
Interpretation: Our results demonstrate that pulmonary live tuberculosis vaccines efficiently revert estab-
lished asthma in mice. These data support the further exploration of this approach as potential therapy
against asthma.
Funding: Spanish Ministry of Science [grant numbers: BIO2014-5258P, RTI2018-097625-B-I00], Instituto de
Salud Carlos III, Gobierno de Aragon/Fondo Social Europeo, University of Zaragoza [grant number: JIUZ-
2018-BIO-01].
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Asthma has reached pandemic levels, with more than 300 million
individuals affected all around the world. Asthma is especially preva-
lent in developed countries compared to low- and middle-income
scenarios. One of the most accepted explanations for these differen-
ces comes from the named “Hygiene hypothesis”, which suggests
that asthma development is favoured by the lower exposure of chil-
dren to determined environmental factors [1]. In this regard, expo-
sure to certain microorganisms and mites (as those present in farms)during early life stages might contribute to educating the immune
system, leading to the acquisition of higher tolerance to allergens
[2,3].
Asthma is a heterogeneous disease characterized by chronic
airway inflammation and remodeling. Even though asthma can
be associated with different types of inflammatory response, type
2 inflammation is present in more than 80% of asthma cases in chil-
dren. T helper (Th) lymphocytes with a Th2 profile are present in
most of the patients, producing cytokines as IL-4, IL-5 or IL-13, which
are responsible for some of the characteristic clinical symptomatol-
ogy. IL-5 plays a central role in the survival and recruitment of eosi-
nophils, one of the main players in asthma, and whose presence in
sputum represents one of the most accepted biomarkers for the
Research in context
Evidence before this study
The current tuberculosis (TB) vaccine, BCG, is the most adminis-
tered vaccine in history. Since BCG, a live-attenuated vaccine, is
classically considered a Th1 response-promoter, the benefits of
intradermal BCG vaccination for asthma have been widely
assessed, although epidemiological evidences are controversial,
with no clear benefits demonstrated. Conversely, different
studies suggest a relationship between higher tuberculosis
infection rates and lower prevalence of asthma. Indeed, we
recently demonstrated this correlation in TB-infected mice sub-
jected to an experimental model of allergen-induced asthma.
Since tuberculosis infection is mostly acquired by the respira-
tory route, whereas BCG is given intradermally, evidences from
human and animal studies suggest that the beneficial effects of
live mycobacteria against asthma might rest on that bacteria
physically reach the lungs to induce an asthma antagonistic
response at a local level.
Added value of this study
In the present study, in an attempt to mimic the natural route of
tuberculosis infection, we investigated the therapeutic efficacy
of intranasal live-attenuated mycobacterial tuberculosis vac-
cines in different acute and chronic murine models of airway
hyperresponsiveness (AHR). Our results showed that intranasal
vaccine administration reverted AHR-associated response in all
scenarios assayed, both in short-term and long-term acute
models, and also in an established asthma scenario induced by
chronic allergen exposure, where a strong airway eosinophilia
was already present prior to vaccine administration. Our results
indicate that vaccine treatment subverted asthma-associated
type 2 response, including repolarization of allergen-specific
Th2 lymphocytes into Th1. In addition, we described for the
first time the use of the live-attenuated mycobacterial TB vac-
cine MTBVAC against asthma. MTBVAC is a vaccine candidate
currently under clinical evaluation, and therefore alternative
applications of this vaccine are relevant from a translational
point of view.
Implications of all the available evidences
From regulatory point of view, aerosol (but not intranasal)
delivery might be the only accepted route of administration for
live tuberculosis vaccines into the lung compartment. In this
study, we have evaluated the efficacy of nebulization in vitro of
two clinical formulations of MTBVAC and BCG in a standard
commercial nebulizer, demonstrating the feasibility of reaching
therapeutic bacterial doses using standard nebulization devices.
Altogether, our data support the further exploration of pulmo-
nary application of live-attenuated mycobacteria as potential
therapy against asthma.
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remodeling by inducing proliferation of airway epithelial cells as well
as exacerbated mucus production [4].
In addition to adaptive response, over the last years different
studies have evidenced the crucial importance of lung innate popula-
tions for asthma triggering. Indeed, allergen presentation through
MHC-II molecules from antigen-presenting cells (APC) results essen-
tial for the induction of allergen-specific T cells [5]. Asthma has been
linked with a pathological macrophage polarization towards an M2
phenotype, as exacerbated levels of M2 macrophages have beenfound in asthma animal models [6,7] as well as in samples from
patients [8]. M2 macrophages adopt regulatory skills and trigger an
immune modulatory environment that impairs Th1 response and
favours expansion of Th2 cells [9]. M2 is a simplified terminology
that encloses different subsets of macrophages with regulatory skills.
Thus, three different types of M2 macrophages have been defined,
M2a, M2b and M2c, each with its own peculiarities. In the particular
case of M2a macrophages, their presence has been linked with an
induction of Th2 adaptive response [10]. With regard to allergic
asthma, M2a macrophages can contribute to triggering the allergen-
specific T cell response by at least two different ways, including pre-
sentation of allergen-derived peptides to T lymphocytes through
MHC-II molecules, and by secretion of cytokines such as IL-4, which
drive T cell response towards a Th2 profile [11]. Therapies targeting
M2 macrophages have been shown to alleviate allergic responsive-
ness [12]. Thus, exacerbated M2 macrophage activation represents a
highly attractive opportunity to design novel immunomodulatory
treatments targeting this misbalance in lung macrophage popula-
tions [13].
The current tuberculosis vaccine BCG is the most administered
vaccine in history. As live-attenuated Mycobacterium bovis, BCG vac-
cine is classically considered a Th1 response-promoting stimulus and
as such, the benefits of intradermal BCG vaccination for asthma have
been widely discussed [14]. Different observational studies suggest
that vaccination with BCG could provide protection in the develop-
ment of certain allergies, including ashtma [15]. Remarkably, an
interventional study conducted in South Korea evidenced that the
group of asthma patients treated with BCG presented an improve-
ment of lung function in the next days following vaccination, in com-
parison with the placebo group [16].
At a preclinical level, whole-cell BCG, either live or inactivated, as
well as different mycobacterial components, have been extensively
proven to be efficient against asthma in different animal models [17-
19]. However, most of these results have been obtained with BCG
delivered prior to or concurrently with allergen sensitization. As a
result, the therapeutic capacity of BCG to revert established asthma
has not been elucidated. In addition, previous studies have focused
mainly on the Th1/Th2 response balance without considering other
components of the immune system, such as pulmonary macrophages,
which seem to play major role during asthma development.
In the present study, we mimicked the natural route of tuberculo-
sis infection by intranasal delivery of live tuberculosis vaccines, to
evaluate the therapeutic efficacy of this approach in different models
of airway hyperresponsiveness (AHR). We hypothesized that direct
interplay between vaccines and the lung compartment might modu-
late the immune environment associated with asthma. Our results
revealed that BCG was able to re-educate M2 macrophages induced
by allergen administration towards an M1 phenotype, as well as to
convert allergen-specific Th2 lymphocytes to Th1. In addition, we
assessed for the first time the efficacy of a live-attenuated Mycobacte-
rium tuberculosis vaccine, called MTBVAC, against asthma. MTBVAC is
currently under clinical evaluation, and to date it remains the first
and only live vaccine based on attenuated M. tuberculosis that has
reached the clinic [20-22]. Importantly, our data showed strong ther-
apeutic efficacy of both BCG and MTBVAC in allergen-challenged
mice in a scenario of established disease, demonstrating the potential
of live attenuated tuberculosis vaccines as therapy for asthma.
2. Materials and methods
2.1. Ethics
Experimental work was conducted in agreement with the Spanish
Policy for Animal Protection RD53/2013 and the European Union
Directive 2010/63 for the protection of animals used for experimental
and other scientific purposes. Experimental procedures were
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sity of Zaragoza. (protocol PI22/15).
2.2. Bacteria
BCG Danish SSI (Pfizer), BCG Pasteur (strain 1173P2, Institut Pas-
teur Paris, France), MTBVAC(20) (University of Zaragoza) and
MTBVACDerp [23] (University of Zaragoza) strains were grown at
37 °C in Middlebrook 7H9 broth (Difco) supplemented with ADC 10%
(Difco) and 0.05% (v/v) Tween-80 (Sigma), Sauton’s medium or on
solid Middlebrook 7H10 (Difco) agar medium supplemented with
ADC 10%. BCG Pasteur and MTBVAC were transformed with the repli-
cative pJKD6 plasmid encoding green fluorescent protein (GFP) (a
kind gift from Luciana Leite, Butantan Institute, Brazil). MTBVAC
heat-killed was obtained by boiling an MTBVAC culture at 100 °C for
15 min. MTBVAC produced under GMP conditions was provided by
Biofabri (Spain). OncoTICE was purchased from MSD. Bacterial sus-
pensions for vaccination were prepared in PBS from glycerol stocks
previously quantified by plating serial dilutions.
2.3. Animal studies
All mice were kept under controlled conditions and observed for
any sign of disease.
For induction of OVA-specific AHR, 8 to 10 weeks old C57BL/6
(Janvier Biolabs) female mice were sensitized by two intraperitoneal
injections of 50mg chicken egg ovalbumin (lyophilized powder,
98% (Sigma)) with 2mg aluminum hydroxide (Sigma, St. Louis, MO)
one week apart. One week after second sensitization, mice were
given a single intranasal administration of BCG, MTBVAC or MTBVAC-
derived vaccine at the dose indicated in the figure legends, resus-
pended in 40ml of PBS. In the acute model, four weeks after vaccine
administration, animals were intranasally challenged with 100mg
OVA in sterile PBS for 3 consecutive days and one day after the last
challenge, mice were humanely sacrificed. In some of the experi-
ments, OVA challenge was delayed until 4 months after BCG vaccina-
tion. In the chronic OVA model, three weeks after immunization,
mice were intranasally challenged wth 10mg OVA twice per week
during eight weeks. In this case, vaccines were administered at week
9 of the procedure, in the middle of the challenge phase. For HDM-
induced chronic AHR, mice were intranasally challenged twice a
week for three consecutive weeks with 10mg HDM. Vaccines were
delivered at week 4 of the experiment (i.e., one week after primary
HDM challenge), and one month later, mice were intranasally chal-
lenged with 10 mg HDM for three consecutive days. One day
after last HDM administration animals were humanely sacrificed.
Dexamethasone treatment was given according to [24]. Briefly, OVA-
sensitized mice were treated intraperitoneally with 5mg/kg dexa-
methasone (DEX) (Dexamethasone-Water Soluble, Sigma-Aldrich)
the day prior to initiating the challenge phase, and then three addi-
tional DEX inoculations were given 1 hour before each OVA intrana-
sal administration.
For bronchoalveolar lavage (BAL) collection, trachea was cannu-
lated and BAL performed with 0.8ml of ice-cold PBS. Supernatant
was separated from cells by centrifugation for 5min at 4500 xg.
Lungs were removed aseptically. For obtaining cellular suspen-
sions, they were added to HEPES buffer (HEPES 10mM; NaCl 0,15M;
KCl 5mM; MgCl2 1mM; CaCl2 1,8mM pH 7,4) containing collage-
nase D 100mg/ml (Roche) and DNAseI 400 IU (AppliChem), incu-
bated at 37 °C for 30 min, and homogenised using GentleMACS
(Miltenyi Biotech) dissociator with the lung specific program accord-
ing to manufacturer instructions. Afterwards, residual red blood cells
were lysed using Red Blood Cells Lysing Buffer (Sigma) and the
homogenized filtered to eliminate tissue debris. For bacterial burden
determination, lungs were homogenized with the GentleMACS, using
the RNA protocol, and then plated onto agar medium 7H10supplemented with ADC. In the case of histological analysis, lungs
were fixed with 4% formaldehyde solution for 24 h prior to the stain-
ing procedure.
2.4. Flow cytometry analysis
106 lung or BAL cells were incubated for 15 min at 4 °C with
Fc receptor blocking reagent (Miltenyi Biotech). Then, eosinophil,
neutrophil and macrophage presence was determined by extra-
cellular staining with the following antibodies: CD45-FITC (RRID:
AB_2658216), siglecF-APC (RRID:AB_2653441), Ly-6G-Vioblue
(RRID:AB_2751964), CD11c-PE (RRID:AB_2654707), CD11b-PerCP/
Cy5.5 (RRID:AB_2751174) from Miltenyi Biotech. Eosinophils
were defined as SSChighCD45+CD11b+SiglecF+CD11c; neutrophils
as CD45+Ly6G+CD11b+CD11c; and Alveolar Macrophages as
CD45+SiglecF+CD11c+CD11bdim cells.
For intracellular staining (ICS), after labeling membrane proteins
with the above-mentioned antibodies, in addition to MHCII-Vioblue
(RRID:AB_2652908) and CD86-PE (RRID:AB_2660746) (Miltenyi),
and CD206-APC (RRID:AB_2739133) (BD Biosciences), cells were
fixed and permeabilized with the FoxP3 staining set (Miltenyi Bio-
tech), according to manufacturer instructions. As intracellular anti-
bodies, we used iNOS-APC (RRID:AB_2727527) and iNOS-PE (RRID:
AB_2727486) (Miltenyi), and Arg1-APC (RRID:AB_2734835)(eBio-
sciences). Cells were acquired using a Gallios flow cytometer (Beck-
man Coulter) and analyzed with Weasel software.
2.5. Cytokine analysis
Quantification of IL-5, IL-4, IL-13 and IFN-g was performed using
specific commercial ELISA kits following manufacturer instructions
(Mabtech Biotech). Cytokine determination in the lungs was done
from organ explants. These were prepared by cutting the lung into
small pieces and incubating them overnight at 37 °C in 0.5ml of cul-
ture medium.
To analyze OVA specific response, mediastinal lymph nodes were
removed aseptically and mechanically disrupted for cell collection.
2£ 106 cells were incubated with or without OVA at 1mg/ml for
96 h. Then, supernatant was collected to determine cytokine concen-
tration. OVA-specific response for each cytokine was calculated as
the difference between cytokine concentration obtained following
OVA stimulation minus the unstimulated control. For ICS, cells were
incubated with 1mg/ml OVA or 1 mg/ml of anti CD3/CD28 (RRID:
AB_394590; RRID:AB_394763, respectively) (BD Biosciences) for
24 h, and 10 mg/ml Brefeldin A (Sigma) was added during the last six
hours. For surface staining, cells were labelled with anti-CD4-FITC
(RRID:AB_394582) (BD Biosciences) and anti-CD3-PerCPVio700
(RRID:AB_2752207) (Miltenyi Biotec) in culture medium with 10%
FCS. Then, cells were fixed and permeabilized with the Cytofix/Cyto-
perm Fixation/Permeabilization Kit (BD Biosciences) following manu-
facturer instructions, and stained with anti-IFNg-APC (RRID:
AB_2784369) and anti-IL5-PE (RRID:AB_2660015) (Miltenyi Biotech).
2.6. qRT-PCR
For RNA extraction, lungs were immersed into TRIzol reagent
(Invitrogen) just upon harvesting, and frozen immediately on dry ice.
Once thawed, lungs were homogenised with the GentleMACS, using
the RNA 0.2 protocol. 200ml of chloroform were added per ml of TRI-
zol and after vigorous vortexing, tubes were centrifuged at 18,000 x g
during one hour at 4 °C. Aqueous upper phase containing eukaryotic
RNA was recovered, added to 700ml of isopropanol and centrifuged
at 18,000 x g during 10 min at 4 °C. The resulting pellet was washed
with 70% EtOH and stored at 20 °C. Residual DNA was eliminated by
DNAse treatment, RNA was purified with an extraction based on phe-
nol-acid-chloroform and precipitated ON at 20 °C with isopropanol
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expression analysis by RT-qPCR. Primer pairs used in the present
study were the following:




















Arg1 50-GCTCCAAGCCAAAGTCCTTAGA 50-CCTCGAGGCTGTCCTTTTGA2.7. Nebulization studies
MTBVAC and OncoTICE GMP vials were resuspended with 1ml/
vial of eluent indicated by manufacturers, concentrations normalized
at 107 CFU/ml, and 2ml of each vaccine preparation placed in the res-
ervoir of the clinical nebulizer U100 (OMRON). Nebulizer was con-
nected with a plastic tube to a gas washing flask with 5ml of sterile
water, coupled with a vacuum pump to recover the nebulized frac-
tion. Bacteria were nebulized for 5 min and both nebulized and reser-
voir fractions were plated on solid agar 7H10 medium supplemented
with ADC. Nebulization efficacy index for each vaccine strain was cal-
culated as the percentage of bacteria in the nebulized fraction com-
pared to that in the reservoir.
2.8. Statistics
Mice were randomly distributed in groups of 6 animals per cage
prior to start experimental procedures. Results were not blinded for
analysis. No statistical method was used to calculate sample size in
animal experiments. GraphPrism software was used for statistical
analysis. Statistical tests used for each experiment are indicated in
the figure legends. All statistical tests used were two-tailed. Outlier
values were determined applying the Grubb’s test to all data sets,
and discarded from the final statistical analysis. Differences were
considered significant at p<0.05.
2.9. Role of funding source
The funders had no role in study design, data collection, interpre-
tation and analysis, decision to publish or preparation of the manu-
script.
3. Results
3.1. Intranasal BCG and MTBVAC prevent AHR in allergen-sensitized
mice
Initially, we tested vaccine efficacy in an acute model of AHR
driven by ovalbumin (OVA) administration. Appearance of asthma
symptoms in humans comes preceded by an asymptomatic phase of
allergen sensitization, which is usual to occur at an early life stage
during childhood [25]. Thus, to make our conclusions morerepresentative of the real situation, we delivered vaccines over previ-
ously sensitized animals (Fig. 1a). With the objective to reach the pri-
mary organ (lungs) affected during asthma episodes, we inoculated
the vaccines by the intranasal route. Our long experience with this
route of administration in mouse models indicate that a substantial
proportion of bacteria reaches the lungs under the experimental set-
tings used. The dose of BCG initially administered was 106 CFUs. As
primary marker of asthmatic responsiveness we measured eosinophil
infiltration in lungs and respiratory airways the day after last chal-
lenge (Fig. 1b, 1c, S1), relevant from a clinical point of view. Our data
revealed a strong ability of intranasal BCG to abrogate eosinophilia
both in BAL and lungs (Fig. 1c-e). In addition, we found no changes in
other myeloid populations, as neutrophils and alveolar macrophages,
suggesting that BCG did not trigger an uncontrolled cellular infiltra-
tion into the respiratory airways and indeed, the number of total leu-
kocytes (CD45+ cells) were significantly lower in the BCG OVA group
compared to OVA (Fig. 1e). Another typical asthma hallmark is the
remodeling of the airway epithelium, which is characterized by a
thickening of the alveolar walls and the proliferation of goblet cells,
responsible for mucus production and secretion. These features were
observed in the lungs from OVA group after staining with Periodic
Acid Schiff (PAS) technique, where different layers of epithelial cells
could be distinguished in the alveolar walls, with an important pro-
portion of PAS-positive cells (goblet cells). In addition, presence of
mucosubstances was found in the airways. Remarkably, BCG treat-
ment prevented this phenotype. Goblet cells were hardly visible and
no mucus secretion was observed in alveolar spaces, whereas airway
epithelium was restricted to one layer (Fig. 1f).
We also assessed intranasal BCG in a long-term AHR model, in
which OVA challenge was performed four months after BCG immuni-
zation. BCG also reduced eosinophilia in this model (Fig. 1g). Interest-
ingly, bacterial counting in lungs at the time of sacrifice indicated
that BCG persistence was dramatically reduced compared to the one-
month model (Fig. S2a), indicating that intranasal BCG could modu-
late asthma-associated immune environment even after almost com-
plete bacterial clearance, which might suggest a contribution of
memory response to the vaccine-protective effect.
MTBVAC is a novel live tuberculosis vaccine, attenuated from a
clinical isolate of Mycobacterium tuberculosis, the pathogen causative
of TB in humans, whereas BCG is a derivative vaccine from Mycobac-
terium bovis [20]. MTBVAC has demonstrated higher efficacy and
immunogenicity than BCG against tuberculosis in different preclinical
models [26], and is currently under clinical evaluation in newborn
[22] (ClinicalTrials.gov Identifier NCT03536117) and adult popula-
tions [21] (NCT02933281) in TB-endemic countries in Africa, showing
acceptable safety and immunogenicity profile to date. In the present
study, we evaluated intranasal MTBVAC for the first time in a model
of asthma. Using the OVA-driven acute AHR model described above,
we observed a strong capacity of intranasal MTBVAC to abrogate
eosinophil infiltration into airways, comparable to that observed
with BCG (Fig. 1h).
To address whether vaccine persistence could affect protection
against asthma, we compared MTBVAC with two other MTBVAC-
derived vaccines: MTBVACDerp strain, which contains an additional
deletion of the gene erp resulting in a hyperattenuated phenotype
with lower persistence as previously described [23] and demon-
strated in this study (Fig. S2b); and MTBVAC killed by heat (MTBVAC
HK). MTBVAC HK did not reduce eosinophils following OVA chal-
lenge, whereas MTBVACDerp showed significant reduction as com-
pared to the OVA group but lower than that observed with MTBVAC
(Fig. 1i). These results suggested an influence of bacterial persistence
on protection. To study this in more detail, we conducted a dose-
response experiment with intranasal BCG and MTBVAC. We observed
robust correlation of the dose with a stronger eosinophilia reduction,
both in BAL (Fig. 1J) and lungs (Fig. 1k). In the case of the lungs, the
highest dose groups (107 MTBVAC and 106 BCG) showed a level of
Fig. 1. Intranasal BCG and MTBVAC prevent allergic airway responsiveness in allergen-sensitized mice. (a) Eosinophils were determined by flow cytometry in an OVA-driven acute
AHRmodel, with mice treated intranasally with 106 BCG CFUs one week after second sensitization. (b) A representative hematoxilin-eosin lung image of OVA-challenged mice. Pres-
ence of eosinophils is highlighted with arrows. (c) Eosinophils were quantified by flow cytometry, corresponding to a population SSChighSiglecF+CD11b+CD11c. A representative
diagram is shown in the figure. (d) Percentage of eosinophils in BAL and lungs with respect to CD45+ cells. (e) Total number of leukocytes, eosinophils, neutrophils and alveolar mac-
rophages (AMs) in BAL determined by flow cytometry. (f) Representative images of PAS-stained fixed lungs from OVA-challenged mice untreated (1,2) or BCG-treated (3,4). (g) Eosi-
nophils in BAL using long-term AHR model, in which OVA challenge was performed 4 months after BCG immunization. (h) Eosinophils in BAL following intranasal treatment with
106 MTBVAC or BCG CFU. (i) Total number of eosinophils in BAL following intranasal treatment with 106 MTBVAC, or the derivative strains MTBVACDerp and MTBVAC Heat-Killed
(HK). (j, k) Eosinophils in BAL (j) and lungs (k) following intranasal treatment with increasing doses of MTBVAC or BCG. (l) BAL eosinophils comparison following BCG, MTBVAC and
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these doses for the subsequent experiments. Finally, we assessed
eosinophilia following intranasal MTBVAC or BCG in comparison
with systemic administration of dexamethasone (DEX), which is a
standard drug used in asthmatic patients. Or results showed compa-
rable eosinophil reduction induced by intranasal MTBVAC and BCG
and systemic DEX administration (Fig. 1l).3.2. Intranasal vaccination subverts asthma-associated lung immune
environment
We hypothesized that the beneficial effects against AHR observed
upon intranasal vaccination could be related with the ability of the
vaccine to locally interact with resident phagocytic cells in the lungs.
To assess in vivo infected cell populations following intranasal immu-
nization, we delivered a BCG strain that expressed the green fluores-
cent protein (GFP). Our data demonstrated that level of BCG infection
was efficient enough to discern infected cells by flow cytometry
(Fig. 2a). Using a panel of antibodies to detect myeloid cell markers,
we identified that the majority of BCG-infected cells corresponded to
alveolar macrophages (AMs). Noteworthy, an important proportion
of infected AMs expressed high levels of iNOS and CD86, two well-
known markers of classical macrophage activation (or M1 pheno-
type) (Fig. 2a). We next compared macrophage polarization of total
lung macrophages in OVA-challenged mice treated or not with BCG.
Percentage of iNOS- and CD86-positive macrophages was substan-
tially higher in the vaccinated group, whereas no difference was
found in the case of MHC-II, with most of the macrophages positive
for this marker in both groups (Fig. 2b). Importantly, expression of
CD206, a classical marker associated with M2 polarization, was
greater in macrophages from OVA group compared to those of the
vaccinated group, which expressed similar levels of CD206 as naïve
cells (Fig. 2c). To complement these data, we performed another
experiment in which we isolated lung RNA from untreated or BCG-
treated OVA-challenged mice. Expression analysis of genes linked
with macrophage polarization clearly demonstrated that BCG immu-
nization led to an upregulation of the M1 profile-associated genes
Nos2 and Il1b, whereas it inhibited expression of the M2 activation
markers Ym1, Arg1 and Retlna (Fig. 2d). Interestingly, in a dose-
response experiment with MTBVAC and BCG, iNOS expression was
found highest in the groups treated with the most protective vaccine
doses (107 MTBVAC and 106 BCG) (Fig. 2e), suggesting a correlation
between M1 phenotype and protection against asthma. Altogether,
our data demonstrated the enrichment of M2-like macrophages dur-
ing asthmatic responsiveness, and suggested that the therapeutic
efficacy of live attenuated mycobacteria could rest on the reversion
of this response by inducing classical activation of lung macrophages.
We next studied pulmonary Th1 and Th2 responses, whose misbal-
ance towards the latter one has been classically connected with the
immune pathogenesis of asthma. Gene expression analysis of lung
RNA revealed that BCG vaccination led to induction of Th1-associated
genes as Ifng, Il12a, or the transcription factor Tbet. Conversely, genes
codifying for typical Th2 cytokines and chemokines, as IL-5, IL-4, IL-13
or CCL-1, were down modulated by BCG (Fig. 3a) compared to
untreated mice. In consonance with these results, IL-5 and IL-4 cyto-
kines were found elevated in BAL and lungs respectively in the OVA
control group, whereas IFNg was increased when treated with BCG
(Fig. 3b, c). In addition to total cytokine levels, we also studied aller-
gen-specific T cells after ex vivo OVA stimulation of harvested lympho-
cytes from mediastinal lymph nodes. Data showed a higher IL-4, IL-5
and IL-13, and lower IFNg OVA-specific production in the OVA group
compared to BCG-vaccinated mice (Fig. 3d-g). Intranasal MTBVAC
showed a similar ability as BCG to shift CD4+ cells towards Th1 profiledexamethasone (DEX) treatment. Data in the graphs are pooled means§SEM from three inde
per group and experiment. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001, by two-way ANOV(Fig. S3). We also found a correlation between vaccine-induced Th1
profile and bacterial dose, indicating the importance of bacterial per-
sistence for the shift of Th2 response toward Th1 (Fig S4).
Importantly, using intracellular staining and flow cytometry we
directly visualized cytokine-producing CD4+ T cells expressing the
memory marker CD44. Both following stimulation with CD3/CD28 or
with OVA, we observed an opposite T cell response polarization
between OVA controls and BCG-treated mice. BCG treatment abro-
gated OVA-specific IL-5-producing cells, whereas it triggered aller-
gen-specific Th1 IFNg-producing CD4+ lymphocytes (Fig. 3h, i). This
suggests that T cell-driven IFNg production in BCG-treated mice is
not only generated by expanded lymphocytes that recognize myco-
bacterial antigens, but also by allergen-specific T cells, that might be
re-shaped from a Th2 towards a Th1 profile due to vaccine-associated
inflammatory environment.
3.3. BCG and MTBVAC inhibit eosinophilia and lung remodeling in a
scenario of established asthma
With the aim to elucidate the therapeutic potential of live attenu-
ated vaccines against established asthma, we conducted experiments
using a chronic AHR model with multiple OVA challenges, where vac-
cines were delivered halfway through the challenge phase (Fig. 4a).
BAL eosinophils were determined in an additional group sacrificed
the day prior to vaccination, at week 8, confirming eosinophil infiltra-
tion at the time of vaccine administration (Fig. 4b). Data at the end of
the procedure, at week 13, revealed that eosinophils were reduced in
the treated group, indicating the capacity of BCG to overcome estab-
lished allergen-induced eosinophilia (Fig. 4c).
In another experiment, we also observed that MTBVAC was able
to revert eosinophilia under similar experimental settings as BCG
(Fig. 4d). In this experiment we additionally assessed lung remodel-
ing by PAS staining and histological evaluation. Our data revealed an
important disorganization of the alveolar epithelium surface in the
OVA control group, as well as a substantial presence of goblet cells.
This phenotype was not observed following MTBVAC treatment
(Fig. 4e). We also analyzed by flow cytometry expression of the M2
and M1 polarization markers Arg-1 and iNOS, respectively. A signifi-
cant proportion of Arg-1-positive macrophages was found in the OVA
group but not in the MTBVAC-treated mice. Conversely, iNOS-posi-
tive macrophages were detected in the MTBVAC group, suggesting
the ability of the vaccine to re-polarize asthma-associated M2 macro-
phages towards M1 profile (Fig. 4f, g).
We next assessed the therapeutic efficacy of intranasal BCG and
MTBVAC in a model of established AHR induced by house dust mites
(HDM), a relevant allergen in clinical asthma. Allergen-induced air-
way responsiveness was triggered by successive intranasal HDM
challenges (Fig. 5a), which elicited a strong eosinophil infiltration in
the BAL (Fig. 5b). BCG and MTBVAC administration resulted in abol-
ishment of BAL eosinophilia, as measured in frequency (Fig. 5b) and
absolute number of cells (Fig. 5c). PAS-stained lungs showed that
HDM exposure in untreated mice strongly induced proliferation of
the alveolar epithelium and appearance of goblet cells, a phenotype
that was not observed in the vaccine-treated groups (Fig. 5d).
Finally, we observed that vaccine administration diminished pro-
duction of Th2 cytokines and substantially increased IFNg in BAL
(Fig. 5e, g) and lymph node cells following stimulation with HDM
(Fig. 5f, h).
3.4. MTBVAC and BCG aerosolization feasibility with a clinical nebulizer
There are strong regulatory safety concerns about intranasal
delivery of vaccines in humans [27]. However, aerosol administrationpendent experiments (d, e, h), two (i), or one (g, j, k, l). A minimum of 6 mice were used
A (a, e,) or by one-way ANOVA (g, h, i, j, k, l), with Bonferroni post-test.
Fig. 2. BCG intranasal infects lung resident macrophages and induces classical activation. (a) Groups of mice were immunized with 106 CFU of GFP-expressing BCG. One month later,
infected cells were monitored and characterized by flow cytometry. Expression of M1-polarization markers iNOS and CD86 was analyzed. Representative diagrams are shown in the
figure. (b) Percentage of iNOS-, CD86- and MHC- positive lung macrophages in OVA-challenged untreated or BCG-treated. (c) Surface expression of the M2-activation marker CD206.
Representative overlay histogram showing CD206 surface expression of indicated experimental groups. Graph shows comparison of Mean Fluorescence Intensity (MFI) correspond-
ing to CD206 level of expression. (d) M1 and M2 activation markers measured by qRT-PCR in lungs from OVA-challenged mice, untreated or BCG-treated. (e) Percentage of iNOS-
positive cells in lung macrophages following intranasal treatment with increasing doses of MTBVAC or BCG. Data in the graphs are representative mean§SEM from two independent
experiments (b, c) or one (d, e). A minimum of 6 mice was used per group and experiment. *p<0.05; **p<0.01; ***p<0.001; by unpaired single (b, c) or multiple (d) t-student test; or
by one-way ANOVA (e) with Bonferroni post-test.
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Fig. 3. BCG intranasal reshapes allergen-specific response into a Th1 profile. (a) Th1 and Th2 activation markers measured by qRT-PCR in lungs from OVA-challenged mice,
untreated or treated with BCG one week after sensitization. (b) IL-5 determination in BAL. (c) IL-4 and IFNg determination in lung explants (d-g) Allergen-specific IL-4, IL-5, IL-13
and IFNg produced by mediastinal lymph node cells, following ex vivo stimulation with OVA. Data are represented following subtraction of the value obtained in the absence of
allergen. (h, i) IL-5- and IFNg- producing cells visualized by intracellular staining and flow cytometry following ex vivo stimulation with anti CD3/CD28 or with OVA. Representative
diagrams are shown. Data in the graphs are pooled means§SEM from three independent experiments (b-e, g) or one (a, i). A minimum of 6 mice was used per group and experi-
ment. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001, by multiple t-student test (a), one-way ANOVA with Bonferroni post-test (b, D-g), and two-way ANOVA with Bonferroni post-
test (c, i).
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Fig. 4. BCG and MTBVAC intranasal revert established allergic airway responsiveness in an OVA-driven chronic model. (a) Scheme of the experiment based on an OVA-induced
chronic model. Sensitized mice were challenged from week 3 to 13 with two intranasal inoculations weekly of OVA 10mg. Vaccines were delivered at week 9, in the half of the chal-
lenge phase. (b) Total number of eosinophils in BAL at week 8, the week before vaccine immunization. (c) Total number of eosinophils in BAL at week 13, four weeks after BCG treat-
ment. (d) Total number of eosinophils in BAL at week 13, four weeks after treatment with 107 CFU of MTBVAC. (e) Representative images of PAS-stained fixed lungs from OVA-
challenged mice untreated or MTBVAC-treated. (f, g) Intracellular expression of iNOS and Arg-1 in lung macrophages at week 13. Representative dot-plot diagrams are shown. Data
in the graphs are pooled means§SEM from two independent experiments (b, c), or one (d, g). A minimum of 6 mice was used per group and experiment. *p<0.05; **p<0.01;
***p<0.001, by t-student test (b, e), one-way ANOVA with Bonferroni post-test (b, c), and multiple t-student test (g).
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Fig. 5. BCG and MTBVAC intranasal vaccination reverts established allergic airway responsiveness induced by the relevant allergen HDM. (a) Scheme of the experiment. Mice were
challenged twice a week during 3 consecutive weeks with intranasal HDM 10mg. Vaccines were delivered the week after. (b) BAL percentage of eosinophils (with respect to CD45+
cells) comparison between week 2 (prior to treatment) and week 7 (end of the procedure), following treatment with MTBVAC or BCG. (c) Total number of eosinophils in BAL at the
end of the procedure. (d) Representative images of PAS-stained fixed lungs from HDM-challenged mice untreated or BCG- or MTBVAC-treated. 10x left panels and 40x right panels
(e, f) Th2 cytokines IL-5, IL-4 and IL-13 were analyzed in BAL, and in lymph nodes following ex vivo stimulation with HDM. (g, h) Th1 cytokine IFNg- was analyzed in BAL, and in
lymph nodes following ex vivo stimulation with HDM. Data in the graphs are mean§SEM from one experiment (n = 6 mice per group). *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001 by one-way ANOVA with Bonferroni post-test (a, c, g, h), and two-way ANOVA with Bonferroni post-test (e, f).
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Fig. 6. MTBVAC and BCG are feasibly nebulized with a clinical device. (a) OMRON U100 nebulizer used in the study. (b) MTBVAC and BCG OncoTICE CFUs determined in nebulized
and reservoir fractions. (c) Nebulization efficacy index calculated as the percentage of bacteria recovered in the nebulized fraction compared to the contained in the reservoir. Each
dot corresponds to the result obtained with a different filter. Data in the graph represents mean§SEM from six independent nebulizations with MTBVAC, and three with BCG
OncoTICE . *p<0.05, by t-student test.
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and multiple commercial nebulizers authorized for human use are
available. From a practical perspective, an important step to bring
pulmonary administration of live mycobacteria to clinical develop-
ment is the feasibility to deliver therapeutic vaccine doses through
the aerosol route. To evaluate this, we measured the nebulization
efficacy of GMP formulations of MTBVAC and BCG (OncoTICE)
adapted for human use, through the clinical nebulizer OMRON U100
(Fig 6a). Bacterial concentration loaded into the reservoir was similar
for both vaccines, around 1.5£ 107 CFUs/ml. After 1 min of nebuliza-
tion, the mean amount of bacteria recovered in the nebulized fraction
was 1.85£ 106 CFUs for MTBVAC and 5£ 105 for BCG (Fig 6b). The
mean efficacy of nebulization with respect to the initial bacterial load
in the reservoir was 11.7% for MTBVAC and 3.1% for OncoTICE
(Fig. 6c).
Studying different characteristics of BCG and MTBVAC vaccines
we noticed a different appearance between MTBVAC and BCG clinical
formulations upon reconstitution (Fig S5a), with BCG showing a
cloudy suspension, whereas MTBVAC suspension was more clear. It is
important to remark that the amount of viable bacteria in both for-
mulations was comparable, and therefore the more turbid aspect of
BCG could be a consequence of a higher proportion of dead bacteria
produced during the manufacturing process. In addition, this could
be related with the higher tendency of BCG to clump during bacterial
growth. As we have observed under laboratory conditions, in the
absence of detergent, MTBVAC tended to grow in suspension,
whereas BCG suspension showed more clumps (Fig. S5b). We also
visualized both individual bacilli of MTBVAC and BCG by electronic
microscopy. Images revealed lower bacterial length of MTBVAC (<1
mm) in comparison to BCG (>2mm) (Fig. S5c).
4. Discussion
Data available in the literature evidence a primary role of lung
innate cells in the development of asthma. Concretely, alternatively
activated or type M2 macrophages are elevated in lungs from asth-
matic individuals, both in animal models and humans. Reasons
behind this pathological macrophage polarization are not clear. A
plausible explanation is that allergens can directly cause damage in
the alveolar epithelium, and macrophages might be alternatively
activated as reaction to the injury to induce a wound-healing
response [28].
In the present study, we evaluated the therapeutic potential of
live attenuated tuberculosis vaccines BCG and MTBVAC delivered by
the intranasal route in different preclinical models of asthma. Our
results are highly robust. Intranasal BCG and MTBVAC revert AHR-
associated response in all scenarios assayed, both in short-term and
long-term acute models, and also in established asthma induced byOVA or HDM, where a strong airway eosinophilia was already present
prior to vaccine administration. Our results showed that airway
eosinophilia reduction induced following single intranasal delivery of
BCG or MTBVAC was comparable to the observed following dexa-
methasone (DEX) treatment achieved after four drug systemic inocu-
lations. This reflects a qualitative difference between treatment with
vaccines or anti-inflammatory standard drugs. Whereas in the former
case, vaccines are administered once and they provided therapeutic
efficacy in the long-term by subverting the asthma-associated
immune response; in the relative to standard treatments their target
are the symptoms instead of the causes of the disease, and therefore
they carry out the beneficial effect only in the short-term, with
the consequence that the patient is usually subjected to a chronic
treatment during the whole life.
BCG and MTBVAC are efficiently internalized by alveolar macro-
phages upon immunization, leading to the expression of M1 markers
like iNOS or CD86. These proinflammatory macrophages might trig-
ger an inflammatory response antagonist to the generated by alterna-
tively activated macrophages usually associated with asthma.
Importantly, our analysis with GFP-expressing BCG bacteria indicates
that not only infected macrophages adopt an M1 phenotype, but also
uninfected cells. This suggests that macrophages initially infected by
vaccine bacteria generate a chain of signals that would lead to activa-
tion of bystander neighbours, favouring the expansion of a response
that globally counterbalances asthma-associated lung environment.
BCG-associated benefits for asthma patients have been exten-
sively studied in the clinic, both in observational studies comparing
asthma prevalence among BCG vaccinated populations [15], and in
interventional controlled trials with two arms vaccinated either with
BCG or placebo [16]. Data are controversial, with studies showing
opposite findings. Reasons to explain this controversy can be attrib-
uted to different aspects, such as age-group (children or adults), dif-
ferent doses of vaccine administered, previous exposure to
mycobacteria, or even use of different BCG substrains. For instance, in
an interventional study conducted in 2002 in South Korea, authors
found an improvement of lung function in the BCG group with
respect to placebo. However, study subjects were mostly BCG-vacci-
nated, since this vaccine is usually administered during childhood in
the country, and importantly, the intradermal BCG dose was
extremely high (58.2£ 107 CFUs) (standard intradermal dose is
5£ 105) [16]. These experimental settings are different from other
studies performed in countries without a history of BCG vaccination,
where a standard dose of BCG would be used. This is the case of
another study from 2008 conducted in the Netherlands, where no
significant benefit was found in the BCG group [29]. Indeed, at least
two meta-analysis reports comparing different published studies
suggested poor association between intradermal BCG vaccination
and low risk of developing allergies [14,30].
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dependent, and therefore BCG needs to be physically present in the
lungs to induce an efficient antagonist response against asthma.
Indeed, subcutaneous BCG is not protective against asthma in mice
[18], a result that we have confirmed with MTBVAC (data not shown).
This agrees with our observation that live mycobacteria must interact
with resident lung macrophages to activate them in a classical way.
Data from the literature regarding asthma incidence and TB infection
and disease could endorse this hypothesis. A significant correlation
between lower prevalence of asthma and TB notification cases has
been reported [31]. A study conducted in individuals with latent TB
infection (LTBI) showed a strong association between tuberculosis
skin test (TST) positivity and lower prevalence of different types of
allergy [32], including asthma. We recently demonstrated this result
using an experimental tuberculosis infection mouse model [33].
Interestingly, Obihara et al. found a substantial reduction of asthma
incidence in the group with the highest TST value, suggesting a corre-
lation between magnitude of the TB-specific immune response and
degree of unspecific protection [32]. TST assay rate of false LTBI posi-
tives is high, mainly due to the interference of the test with BCG vac-
cine or environmental mycobacteria. However, the authors found the
lower asthma prevalence in the group with higher TST positivity
(>20mm), which makes more likely that this unspecific benefit could
be due to latent tuberculosis infection [34,35].
Finally, reports of individual cases have described lower rates of
exacerbations in asthmatic patients who suddenly undergo active TB
[36]. Since M. tuberculosis infection is mostly acquired by the respira-
tory route (whereas BCG is given intradermally), we speculate that
our results might be reflecting a natural unspecific protection against
asthma that already occurs in nature.
Allergen-specific CD4+ T cells are thought to play a central role in
asthma pathogenesis. Use of allergen-MHC-II tetramers has allowed
characterization of allergen-specific CD4+ T cells in asthmatic individ-
uals, finding tetramer-positive T cell clones that express central
memory markers [37]. These long-lived T cells are ultimately respon-
sible of the perpetuation of asthma throughout lifetime. Upon aller-
gen exposure, specific memory CD4+ T cells migrate to lungs where
they efficiently recognize allergen-derived peptides presented by
APCs, and respond quickly by secreting Th2-associated cytokines
leading to asthma inflammatory response. Thus, a therapy that pur-
sues asthma abrogation should focus on hampering allergen-specific
Th2 memory cells. For instance, immunotherapy based on low-level
allergen epitope exposure works by inducing anergy on allergen-spe-
cific Th2 T cells [38].
Our results analysing OVA-specific T cells in draining lymph
nodes indicate that intranasal vaccines have a strong impact in
OVA-specific Th2 cells. Intracellular staining and flow cytometry,
which allows direct visualization of cytokine-producing cells,
showed a population of IL-5-producing T cells in the OVA group
that is diminished upon BCG treatment, as long as a population
of OVA-specific IFNg-producing cells arises. This suggests that
live mycobacteria could reshape the phenotype of T cells involved
in asthma responsiveness. Interestingly, BCG-induced protection
against AHR was also observed in long-term studies (where OVA
challenge was delayed until 4 months post immunization),
though bacteria were almost totally cleared at the time of analy-
sis, suggesting that vaccines might be triggering allergen-specific
memory T cells with a Th1 profile that persisted even after bacte-
rial clearance, and which could provide a long-lasting protection
against allergen exposure.
A question that remains unanswered in the present study is
whether the T cells that adopt a Th1 profile after immunization are
generated de novo from naïve T cells, or they are the same Th2 clones
induced by allergen exposure, which are re-polarized to Th1 by the
effect of the vaccine. Supporting the second hypothesis, T cells pres-
ent high plasticity and Th2 cells have been shown to become Th1 inthe presence of an appropriate environment enriched with interferon
and IL-12 [39].
Our results demonstrate in mice the efficacy of intranasal BCG and
MTBVAC subverting AHR. Nevertheless, it is unlikely that intranasal
route is authorized for live tuberculosis vaccine delivery in clinic.
Together with the anatomical limitations associated with this route
[40], there are safety concerns with intranasal administration. A flu
vaccine intranasally delivered caused transient face palsy episodes in
clinic [27]. In addition, proximity of the nose cavity to the brain
would be likely a cause of reluctance for regulatory authorities. Con-
versely, the aerosol route results more plausible [41]. Recent studies
in non-human primates (NHP) have demonstrated that BCG reaches
the lungs following aerosolization with clinical nebulizers [42,43].
With regard to human studies, BCG has been already administered in
the past by the aerosol route without major toxicity issues [44,45],
and at present there are at least two on-going clinical trials to assess
safety of aerosol BCG (NCT03912207, NCT02709278). Interestingly,
our results showed the feasibility of nebulizing GMP formulations of
MTBVAC and BCG through a clinical nebulizer, reaching bacterial
loads proven to be effective in models of established asthma. Of note,
our data indicated that MTBVAC was more efficiently nebulized than
BCG. As mentioned above, two distinct phenotypic characteristics
between MTBVAC and BCG could account for the different nebuliza-
tion efficiency of the vaccines. Considering that the mean particle
size released by clinical nebulizers is around 5 mm, it is realistic to
speculate that clumping and bacterial size could crucially affect the
efficacy of vaccine nebulization. In this regard, MTBVAC presents a
reduced clumping capacity during growth and smaller bacterial size
compared to BCG. This could be due to the loss of most of the extract-
able surface lipids in MTBVAC as a result of the deletions in the viru-
lence genes phoP and fadD26 [20]. Indeed, phoP mutant strains show
a reduced cording factor [46], which is highly related to clumping in
wild-type strains. Intradermal MTBVAC is in advanced clinical devel-
opment in TB-endemic countries today with demonstrated safety, at
least comparable to BCG, and superior immunogenicity characterized
by antigen-specific Th1 responses in both adult and newborn popula-
tions [21,22]
Although BCG was initially conceived as a prophylactic vaccine
against TB, other different clinical applications have been subse-
quently proposed. The most remarkable one has been the intravesical
application of BCG as bladder cancer therapy, successfully used for
the last four decades. However, no previous therapeutic application
of pulmonary BCG has been reported up-to-date. From a safety per-
spective, a key step to move this type of treatment into clinic should
be to evaluate the reactogenicity of the vaccine in individuals pre-
exposed to mycobacteria, including BCG vaccination and/or M. tuber-
culosis infection. In this regard, a recent study conducted in South
Africa described the safety of a pulmonary BCG administered by the
intratracheal route [47]. Interestingly, the authors inoculated BCG in
adult populations with different mycobacterial sensitization status,
including BCG-vaccinated and latent (pulmonary) TB infected, finding
no major adverse events associated with intratracheal administration
of BCG. In the case of intradermal MTBVAC, a phase IIa dose-escala-
tion study for safety and immunogenicity is currently being per-
formed in M. tuberculosis infected and uninfected adults (BCG-
vaccinated at birth) in South Africa (NCT02933281).
Over the last years, novel experimental immunotherapies against
asthma have emerged, mainly based on the monoclonal antibody-
mediated blockade of specific molecules that contribute to asthma-
induced inflammation, such as IL-4, IL-5, Il-13 or IgE, showing in
many cases positive results. However, these studies also evidence
that efficacy achieved by inhibition of a single pathway is in general
partial. For instance, IL-5-specific therapy substantially inhibits eosin-
ophilia, whereas outcomes for other measures, such as lung function,
are less favourable [48]. Since asthma is a highly complex disease, we
speculate that an approach as the proposed in the present study,
R. Tarancon et al. / EBioMedicine 64 (2021) 103186 13with a capacity to interact with both innate and adaptive immune
components, could be more efficient dealing with the different
aspects of the pathology.
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